Collectively, significant improvement in biopsy‐confirmed liver histology with GLP‐1RAs treatment provides the most substantial evidence for the efficacy of GLP‐1RAs in the management of NASH, although the role of GLP‐1 RAs is still needed to be validated in large sample controlled trials with long‐term follow‐up. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.